Immupharma Plc (IMM) Ordinary 1p

Sell:1.53pBuy:1.71p0.10p (6.41%)

Prices delayed by at least 15 minutes
Sell:1.53p
Buy:1.71p
Change:0.10p (6.41%)
Deal now
Prices delayed by at least 15 minutes
Sell:1.53p
Buy:1.71p
Change:0.10p (6.41%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

ImmuPharma PLC is a specialist drug discovery and development company. The Company is engaged in the development of drugs, largely based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases with high medical need. Its lead program, P140, is a non-immunosuppressing, convenient and safe peptide treatment for autoimmune disease, which is in late-stage development for the treatment of systemic lupus erythematosus (SLE) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Its pipeline products in the anti-infectives inflammation therapeutic areas include BioAMB and BioCin. BioAMB is an advanced anti-infective candidate. It is an improved form of amphotericin-B (AMB), a systemic antifungal drug. BioCin is an improved form of vancomycin, a systemic antibacterial which is highly effective against Methicillin-resistant Staphylococcus Aureus (MRSA) and orally against Clostridium Difficile infections.

Key people

Timothy Mccarthy
Executive Chairman of the Board, Chief Executive Officer
Ashley Clarke
Chief Financial Officer and Company Secretary, Executive Director
Timothy Gary Franklin
Chief Operating Officer, Executive Director
Lisa Baderoon
Non-Executive Director and Head of Investor Relations
Sebastien R. Goudreau
Non-Executive Independent Director
Laurence Robert Reilly
Senior Non-Executive Independent Director
Click to see more

Key facts

  • EPIC
    IMM
  • Location
    United Kingdom
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    GB0033711010
  • Market cap
    £8.00m
  • Employees
    6
  • Shares in issue
    499.72m
  • Exchange
    London Stock Exchange (LON)
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.